(redirected from kallikrein)
Also found in: Dictionary, Medical, Encyclopedia, Wikipedia.
References in periodicals archive ?
Potential involvement of kallikrein hK2 in the hydrolysis of the human seminal vesicle proteins after ejaculation.
The poster, titled "Discovery and characterization of a fully human monoclonal antibody inhibitor of plasma kallikrein for the treatment of plasma kallikrein-mediated edema," (poster #116) highlighted results of preclinical work that was designed to evaluate the activity of DX-2930 as a long-acting inhibitor of plasma kallikrein (pKal).
Further studies by the Joslin researchers showed that normalizing blood glucose levels in diabetic animals could block the effect from plasma kallikrein, and that rapidly inducing hyperglycemia in control animals mimicked the effects of diabetes on brain hemorrhage.
Evaluation of kallikrein in human parotid and submandibular saliva.
Bronchial tissue kallikrein activity is regulated by hyaluronic acid binding.
The C1-Inh product, however, carries the potential risk of blood-borne viruses and is a non-specific inhibitor of kallikrein.
In the future, the research will be directed toward elucidating the kallikrein role in cancer progression.
Chromatography resins, [alpha]-N-benzoyl-L-arginine ethyl ester HCl (BAEE), bradykinin, kallikrein, bovine plasma and SDS-PAGE molecular weight standards were obtained from Sigma Chemical Company.
Comparison of human prostate specific glandular kallikrein 2 and prostate specific antigen gene expression in prostate with gene amplification and overexpression of prostate specific glandular kallikrein 2 in tumor tissue.
Ample evidence suggests that members of the kallikrein family are differentially produced in several cancer types, particularly in hormone-dependent malignancies such as prostate, ovarian, breast, and testicular cancers (13).
announced today the award of a competitively renewed Phase II SBIR grant from the National Eye Institute, at the National Institutes of Health (Bethesda, Maryland), in continuing support of ActiveSite's R&D program on novel orally-active plasma kallikrein (PK) inhibitors for treatment of diabetic macular edema (DME), the primary vision-threatening complication of diabetes.